MSA’s Chief Science Officer, Kenneth Dretchen, PhD is a co-author on second paper on the detection of Aripirazole in urine

December 4, 2014

Clinical Trial correlates urine metabolite concentration with dose of orally administered aripiprazole (Abilify) – October 10, 02014

Dr. Dretchen, MSA CSO, is a co-author on a manuscript accepted for publication in Psychopharmacology entitled “Quantitative Levels of Aripiprazole Parent Drug and Metabolite in Urine”. The results of this study showed that there was a quantitative relationship between the doses of Aripiprazole administered orally and the level of a specific metabolite measured in the urine.

MSA News

Internship Experience Reflection – Kaitlyn Wylie

I never thought my first job would be in the biotechnology and pharmacy industry, let alone with such a passionate…

Read More

MesaGreen Pharmaceutical Company Files an Investigational New Animal Drug Application

FREDERICK, MD.  Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…

Read More

Mesa Science Associates Receives Grant to Begin Study of a Treatment for Marfan Syndrome

Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…

Read More